Signs of low-grade systemic inflammation in female offspring of women with type 1 diabetes: The EPICOM study
Boisen, A.B, Knorr, S, Hansen, T.K, Vlachova, Z, Bytoft, B, Damm, P, Beck-Nielsen, H, Jensen, D.M, Møller, H.J, Gravholt, C.H
Published in Diabetes & metabolism (01.12.2016)
Published in Diabetes & metabolism (01.12.2016)
Get full text
Journal Article
897 CONSENSUS RECOMMENDATIONS FOR VIROLOGIC NOMENCLATURE IN DAA CLINICAL TRIALS
Jensen, D.M, Wedemeyer, H, Godofsky, E.W, Mani, N, Miller, V
Published in Journal of hepatology (01.04.2012)
Published in Journal of hepatology (01.04.2012)
Get full text
Journal Article
P1226 NS3 Q80K DID NOT IMPACT EFFICACY OR TREATMENT-EMERGENT RESISTANCE PATTERNS IN HCV GENOTYPE 1-INFECTED PATIENTS RECEIVING FALDAPREVIR + PEGINTERFERON/RIBAVIRIN IN THREE PHASE III TRIALS
Berger, K, Sarrazin, C, Ferenci, P, Jensen, D.M, Jacobson, I.M, Stern, J.O, Quinson, A.-M, Scherer, J, Kukolj, G
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
706 DIVERGENCE FROM AASLD HCC SURVEILLANCE GUIDELINES LEADS TO UNNECESSARY TESTING AND RADIATION EXPOSURE
Gaetano, J.N, Choi, C.P, Te, H, Aronsohn, A, Reddy, K.G, Jensen, D.M, Reau, N.S
Published in Journal of hepatology (01.04.2012)
Published in Journal of hepatology (01.04.2012)
Get full text
Journal Article
P1227 FALDAPREVIR EFFICACY IN HCV GENOTYPE-1-INFECTED PATIENTS IN FOUR PHASE 3 TRIALS: ANALYSIS BY NS3 BASELINE POLYMORPHISMS, GENOTYPE-1 SUBTYPE AND GENOTYPE-1A CLADES
Berger, K, Sarrazin, C, Jacobson, I.M, Jensen, D.M, Ferenci, P, Dieterich, D, Stern, J.O, Quinson, A.-M, Scherer, J, Kukolj, G
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P1129 EFFECT OF HCV GENOTYPE-1 SUBTYPE ON RESPONSE TO FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: POOLED DATA FROM PHASE III TRIALS
Jacobson, I.M, Jensen, D.M, Dieterich, D, Sarrazin, C, Foster, G.R, Yoshida, E.M, Nelson, M, Ingiliz, P, Soriano, V, Cooper, C, Stern, J.O, Quinson, A.-M, Kukolj, G, Scherer, J, Drulak, M, Gallivan, J.-P, Schobelock, M, Ferenci, P
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P1131 SIMILAR ADJUSTED SVR12 RATES FOR HIV CO-INFECTED AND HCV MONO-INFECTED PATIENTS AND NO DOSE OR POPULATION (TREATMENT-NAIVE/RELAPSER) EFFECT: POOLED ANALYSIS OF FALDAPREVIR PHASE III TRIALS
Dieterich, D, Ferenci, P, Jacobson, I.M, Negro, F, Puoti, M, Rockstroh, J.K, Manns, M.P, Arastéh, K, Oliveira, C, Dufour, J.-F, Zehnter, E, Leen, C, Bhagani, S, Stern, J.O, Quinson, A.-M, Scherer, J, Manero, M, Jensen, D.M
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P1122 COMPARISONS OF POPULATIONS IN FALDAPREVIR PHASE III STUDIES BASED ON PEGYLATED INTERFERON a-2a AND RIBAVIRIN-PREDICTED RESPONSIVENESS AND IMPACT ON ACHIEVING SVR12
Ferenci, P, Jensen, D.M, Dieterich, D, Jacobson, I.M, Romero-Gómez, M, Foster, G.R, Asselah, T, Cooper, C, Tural, C, Streinu-Cercel, A, Ryder, S, Puoti, M, Tam, E, Calleja, J.L, Núñez, M, Quinson, A.-M, Böcher, W, Voss, F, Scherer, J
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P1125 PHARMACOKINETIC-RESPONSE ANALYSIS OF FALDAPREVIR IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: A POOLED ANALYSIS OF TWO PHASE III TRIALS
Foster, G.R, Cooper, C, Dieterich, D, Ferenci, P, Crespo, J, Diago, M, Dufour, J.-F, Lee, W.M, Maevskaya, M, Müllhaupt, B, Wright, D, Schuchmann, M, Wright, M, Bourlière, M, Nishiguchi, S, Abergel, A, Streinu-Cercel, A, Tanaka, Y, Tomita, E, Stern, J.O, Scherer, J, Olson, S, Gallivan, J.-P, Jensen, D.M
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS
Ferenci, P, Dieterich, D, Zeuzem, S, Mantry, P, Sarrazin, C, Crespo, J, Tam, E, Dufour, J.-F, Yoshida, E.M, Nishiguchi, S, Bourlière, M, Omata, M, Abergel, A, Kuboki, M, Carvalho, A, Peng, C.-Y, Romero-Gómez, M, Wright, D, Stern, J.O, Böcher, W, Kukolj, G, Gallivan, J.-P, Scherer, J, Jensen, D.M
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES
Asselah, T, Jensen, D.M, Foster, G.R, Sulkowski, M.S, Ouzan, D, Morano, L, Buynak, R, Agarwal, K, Hassanein, T, Forton, D, Negro, F, Genné, D, Kaita, K, Maieron, A, Preotescu, L, Sarrazin, C, Zehnter, E, Romero-Gómez, M, Stern, J.O, Quinson, A.-M, Drulak, M, Garcia, M, Voss, F, Böcher, W, Ferenci, P
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS
Zeuzem, S, Jensen, D.M, Carvalho, A, Diago, M, Feinman, S.V, Kowdley, K.V, Kao, J.-H, Maevskaya, M, Negro, F, Mantry, P, Tanaka, Y, Forton, D, Genné, D, Paik, S.W, Zehnter, E, Kuboki, M, Lee, W.M, Peng, C.-Y, Yatsuhashi, H, Stern, J.O, Datsenko, Y, Drulak, M, Voss, F, Böcher, W, Ferenci, P
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION
Asselah, T, Jensen, D.M, Foster, G.R, Sulkowski, M.S, Ouzan, D, Morano, L, Buynak, R, Agarwal, K, Hassanein, T, Forton, D, Cho, M, Genné, D, Kaita, K, Maieron, A, Preotescu, L, Sarrazin, C, Zehnter, E, Streinu-Cercel, A, Stern, J.O, Datsenko, Y, Drulak, M, Voss, F, Quinson, A.-M, Ferenci, P
Published in Journal of hepatology (01.04.2014)
Published in Journal of hepatology (01.04.2014)
Get full text
Journal Article
1158 SUBTYPE 1B DOES NOT CONFER A TREATMENT ADVANTAGE TO HCV INFECTED AFRICAN AMERICAN PATIENTS TREATED WITH PEG+RBV
Jenkins, E, Reau, N, Aronsohn, A, Mohanty, S, Reddy, K.G, Jensen, D.M
Published in Journal of hepatology (01.03.2011)
Published in Journal of hepatology (01.03.2011)
Get full text
Journal Article
818 HCV-TARGET: A LONGITUDINAL, OBSERVATIONAL STUDY OF NORTH AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (HCV) TREATED WITH BOCEPREVIR OR TELAPREVIR
Fried, M.W, Reddy, K.R, Di Bisceglie, A.M, Jensen, D.M, Jacobson, I.M, Sulkowski, M.S, Terrault, N.A, Afdhal, N.H, Gordon, S.C, Pockros, P.J, Kwo, P.Y, Everson, G.T, Sherman, K.E, Muir, A.J, Pearlman, B.L, Stewart, T.G, Vainorius, M, Peter, J.A, Nelson, D.R
Published in Journal of hepatology (01.04.2013)
Published in Journal of hepatology (01.04.2013)
Get full text
Journal Article
1180 A CHROMOSOME 19 SNP (RS12979860) PREDICTS OUTCOME (EVR/SVR) IN HCV PATIENTS TREATED WITH INTERFERON, INDEPENDENT OF PEGYLATION OR RIBAVIRIN
Asselah, T, Essioux, L, Marcellin, P, Fried, M.W, Jensen, D.M, Germer, S, Benayed, R, Chu, T, Tietz, A, Chin, D, Shulman, N, Thommes, J.A, Laughlin, M, Lopatin, U
Published in Journal of hepatology (2010)
Published in Journal of hepatology (2010)
Get full text
Journal Article
778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS
Zeuzem, S, Nelson, D.R, Andreone, P, Ferenci, P, Herring, R, Jensen, D.M, Marcellin, P, Pockros, P, Rodriguez-Torres, M, Rossaro, L, Rustgi, V.K, Sepe, T, Sulkowski, M, Thomason, I.R, Yoshida, E, Chan, A, Hill, G
Published in Journal of hepatology (2010)
Published in Journal of hepatology (2010)
Get full text
Journal Article
620 IDENTIFYING PATIENTS WITH A HIGH LIKELIHOOD OF ACHIEVING AN SVR FOLLOWING RE-TREATMENT WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN: USE OF POSITIVE PROGNOSTIC FACTORS (PPF'S)
Jensen, D.M, Craxi, A, Brandão-Mello, C.E, Di Bisceglie, A.M, Andreone, P, Freilich, B, Reddy, K.R, Martin, A. Oliveira, Teuber, G, Messinger, D, Thommes, J.A, Tietz, A, Marcellin, P
Published in Journal of hepatology (2009)
Published in Journal of hepatology (2009)
Get full text
Journal Article